GUANGNAN (HOLD) announced its interim results, with shareholders' profit attributable to shareholders of HKD 76.207 million, an increase of 32% year-on-year
GUANGNAN (HOLD) announced its interim results for the period ending June 30, 2025, with revenue of HKD 6.081 billion, a year-on-year increase of 12%; profit attributable to shareholders was HKD 76.207 million, a year-on-year increase of 32%. The basic earnings per share were HKD 0.084, and an interim dividend of HKD 0.025 per share is proposed. Revenue from the food biotechnology business was HKD 5.019 billion, accounting for 83% of total revenue, a year-on-year increase of 13%. The performance of joint ventures improved, turning losses into profits
According to the Zhitong Finance APP, GUANGNAN (HOLD) (01203) announced its interim results for the six months ending June 30, 2025. The group achieved revenue of HKD 6.081 billion, an increase of 12% year-on-year; the profit attributable to shareholders was HKD 76.207 million, an increase of 32% year-on-year; basic earnings per share were HKD 0.084, and an interim dividend of HKD 0.025 per share is proposed.
The revenue from the food biotechnology business was HKD 5.019 billion, accounting for 83% of the group's revenue, an increase of HKD 589 million, or 13%, compared to the same period last year. The segment profit from the food biotechnology business (excluding profits from joint ventures) was HKD 91.8 million, a decrease of 5% year-on-year. In addition, the performance of the joint venture engaged in live pig farming and sales continued to improve, with the group's share of joint venture profits at HKD 14.55 million (June 30, 2024: share of losses HKD 18.77 million), turning a loss into a profit. Including the share of joint venture profits, the segment profit from the food biotechnology business was HKD 106 million, an increase of HKD 28.21 million, or 36%, compared to the same period last year
